Xenon Pharmaceuticals Inc. (XENE) Financial Statements
Xenon Pharmaceuticals Inc. (XENE) reported trailing twelve-month revenue of $0 (up 2045.7% year on year) and net income of -$409.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$338.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XENEXenon Pharmaceuticals Inc.Follow XENE — free
—
Price chart with a free account
- Market cap
- 3.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.02 | 0.00 | 0.00 | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | |
| Research & development | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.08 | 0.11 | 0.30 | 0.35 | |
| Operating income | 0.01 | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | -0.08 | -0.13 | -0.37 | -0.44 | |
| Pre-tax income | 0.01 | — | — | — | -0.04 | -0.03 | -0.08 | -0.13 | -0.34 | -0.41 | |
| Income tax | 0.00 | — | — | — | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | -0.00 | |
| Net income | 0.01 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.08 | -0.13 | -0.35 | -0.41 | |
| Diluted EPS ($) | 3.28 | -1.10 | -1.48 | -1.72 | -1.54 | -0.81 | -1.77 | -2.06 | -4.36 | -4.10 | |
| Diluted shares (bn) | 0.004 | 0.014 | 0.015 | 0.018 | — | 0.035 | 0.044 | 0.061 | 0.079 | — |
USD billions · SEC XBRL
Xenon Pharmaceuticals Inc. — questions
- What is Xenon Pharmaceuticals Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 2045.7% year on year, from its 10-Q and 10-K filings.
- What is Xenon Pharmaceuticals Inc.'s net income?
- -$409.2M over the twelve months to 2026-06-30.
- What is Xenon Pharmaceuticals Inc.'s free cash flow?
- -$338.5M over the twelve months to 2026-06-30.
- What are Xenon Pharmaceuticals Inc.'s diluted earnings per share?
- $-4.10 over the twelve months to 2026-06-30.
Every figure on this page comes from Xenon Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.